Top Markets
#1 DogBull DogBull +105.03%
#2 ADO Protocol ADO Protocol +63.41%
#3 Siacoin Siacoin +51.97%
#4 MarsCoin MarsCoin +37.49%
#5 Useless Coin Useless Coin +32.42%
#6 Ontology Gas Ontology Gas +27.76%
#7 UnifAI Network UnifAI Network +27.18%
#8 Glidr Glidr +19.86%
#9 Falcon Finance Falcon Finance +17.27%
#10 Apertum Apertum +14.82%
Coin of the day
DogBull DogBull
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Kedudukan dalam Saham #15974
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Harga Saham
$15.42
Modal Pasaran
$320.83M
Perubahan (1 hari)
-1.52%
Perubahan (1 tahun)
40.67%
Negara
IT
Perdagangan Newron Pharmaceuticals S.p.A. (NP5)

Kategori

Healthcare
Pendapatan untuk Newron Pharmaceuticals S.p.A. (NP5)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Newron Pharmaceuticals S.p.A., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Newron Pharmaceuticals S.p.A. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH